Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer

Nicholas Mai,Sara Myers,Sherry Shen,Stephanie Downs-Canner,Mark Robson,Larry Norton,Yuan Chen,Tiffany Traina,Nour Abuhadra

DOI: https://doi.org/10.1038/s41523-024-00643-5

2024-06-05

npj Breast Cancer

Abstract:The KEYNOTE-522 (KN522) regimen for neoadjuvant treatment of triple negative breast cancer (TNBC) utilized q3week dosing for doxorubicin plus cyclophosphamide (AC); however, dose-dense AC (ddAC) has demonstrated superior overall survival (OS) compared to q3week AC in anthracycline and taxane-based regimens. We performed a retrospective analysis assessing the use of ddAC in KN522 and the impact of sequencing ddAC before or after carboplatin/paclitaxel (CbT) plus pembrolizumab on multiple outcomes. 128 patients with TNBC were included. Overall pathologic complete response (pCR) rate of 56%. Sequencing of ddAC vs CbT first showed no difference in pCR rate (ddAC 55% vs. CbT 58%, p = 0.77). However, ddAC first compared to CbT first correlated with a significant increase in the incidence of overall treatment delays (ddAC 70% vs. CbT 51%, p = 0.03), with cytopenias most frequent (ddAC 59% vs. CbT 31%, p = 0.001). ddAC in a modified KN522 regimen is safe, tolerable, and effective. Efficacy is comparable regardless of chemotherapy sequencing, but ddAC first is significantly associated with higher rates of treatment delays and cytopenias.

oncology

What problem does this paper attempt to address?

This paper aims to explore the feasibility and safety of using dose - dense doxorubicin plus cyclophosphamide (ddAC) in the modified KEYNOTE - 522 (KN522) regimen for the treatment of triple - negative breast cancer (TNBC), and to evaluate the specific effects of different chemotherapy sequences (using ddAC first or using carboplatin/paclitaxel plus pembrolizumab, i.e., CbT first) on efficacy and toxicity.

### Background and Research Questions
- **Background**: The standard systemic treatment for stage II - III TNBC is based on the results of the KEYNOTE - 522 trial, including neoadjuvant chemotherapy immunotherapy. In this trial, patients received four cycles of pembrolizumab combined with carboplatin and paclitaxel (CbT) once every three weeks before surgery, followed by four cycles of pembrolizumab combined with doxorubicin plus cyclophosphamide (AC) or epirubicin plus cyclophosphamide once every three weeks. However, other studies have shown that dose - dense doxorubicin plus cyclophosphamide (ddAC) is more effective than AC once every three weeks in some cases.
- **Research Questions**:
- Explore the feasibility and safety of using ddAC in the modified KN522 regimen.
- Evaluate the effects of different chemotherapy sequences (using ddAC first or using CbT first) on the pathological complete response rate (pCR), treatment delay, and toxicity.

### Research Methods
- **Research Design**: Retrospective analysis.
- **Research Subjects**: 128 TNBC patients who received the modified KN522 regimen treatment at Memorial Sloan Kettering Cancer Center from August 2021 to September 2022.
- **Treatment Regimens**:
- Patients received four cycles of CbT (paclitaxel 80 mg/m² once a week and carboplatin AUC 5 once every three weeks), along with pembrolizumab 400 mg once every six weeks.
- Patients received four cycles of ddAC (doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² once every two weeks), with granulocyte colony - stimulating factor (G - CSF) support.
- Patients could receive ddAC first or CbT first, and the specific sequence was determined by the doctor.

### Main Results
- **Overall Efficacy**:
- The overall pCR rate was 56%.
- Multivariate regression analysis showed that younger diagnosis age (p = 0.04), lower clinical T - stage (p = 0.003), positive lymph node status (p = 0.007), and carboplatin AUC 5 once every three weeks (p = 0.03) were significantly associated with a higher pCR rate.
- **Toxicity and Treatment Delay**:
- 61% of patients had chemotherapy delays due to treatment - related toxicity, and 30% of patients had immunotherapy delays.
- 70% of patients had treatment delays for any reason, and the vast majority of them were due to myelosuppression (75%).
- Neutropenia was the most common type of myelosuppression, accounting for 86% of all myelosuppression.
- **Effects of Different Chemotherapy Sequences**:
- Using ddAC first or CbT first had no significant impact on the pCR rate (ddAC 55% vs. CbT 58%, p = 0.77).
- The proportion of patients with treatment delays was significantly higher in those who used ddAC first than in those who used CbT first (ddAC 70% vs. CbT 51%, p = 0.03), mainly due to myelosuppression (especially neutropenia).

### Discussion
- **Conclusions**:
- Using ddAC instead of AC once every three weeks does not affect the efficacy of neoadjuvant chemotherapy immunotherapy.
- Different chemotherapy sequences have no significant impact on the pCR rate, but using ddAC first will increase the risk of treatment delay and myelosuppression.
- Using carboplatin AUC 5 once every three weeks may be associated with a higher pCR rate and a lower treatment delay rate.
- **Limitations**:
- This study is a retrospective non - randomized study, and there is selection bias.
- The overall health status of the study population is good, which may affect the universality of the results.
- As a large - scale cancer center, MSK has abundant resources to support dose - dense chemotherapy and the management of its complications, which may not be feasible in low - volume centers.

### Recommendations
- **Clinical Recommendations**:
- For the modified KN522 regimen, it is recommended to use four cycles of carboplatin AUC 5 once every three weeks and weekly...